Capital World Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital World Investors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.57B	Sell	10,802,348 -5,499,424	-34%	-$1.87B	0.49%	53
2025 Q4	$6.48B	Sell	16,301,772 -132,481	-0.8%	-$58.6M	0.88%	26
2025 Q3	$7.49B	Sell	16,434,253 -370,754	-2%	-$151M	1.02%	19
2025 Q2	$5.48B	Buy	16,805,007 +55,384	+0.3%	+$15.3M	0.8%	27
2025 Q1	$4.52B	Buy	16,749,623 +149,098	+0.9%	+$38.3M	0.73%	33
2024 Q4	$3.91B	Buy	16,600,525 +92,101	+0.6%	+$24.2M	0.59%	38
2024 Q3	$4.54B	Buy	16,508,424 +1,537,081	+10%	+$400M	0.7%	29
2024 Q2	$3.64B	Buy	14,971,343 +2,182,107	+17%	+$344M	0.59%	39
2024 Q1	$1.91B	Sell	12,789,236 -3,385,327	-21%	-$565M	0.32%	83
2023 Q4	$3.1B	Sell	16,174,563 -354,745	-2%	-$60.4M	0.55%	45
2023 Q3	$2.93B	Buy	16,529,308 +31,757	+0.2%	+$6.06M	0.58%	45
2023 Q2	$3.13B	Buy	16,497,551 +21,350	+0.1%	+$4.23M	0.6%	42
2023 Q1	$3.3B	Buy	16,476,201 +85,926	+0.5%	+$18.1M	0.68%	35
2022 Q4	$3.9B	Buy	16,390,275 +2,440,628	+17%	+$521M	0.83%	22
2022 Q3	$2.79B	Buy	13,949,647 +3,658,635	+36%	+$698M	0.63%	35
2022 Q2	$1.5B	Buy	10,291,012 +4,291,338	+72%	+$609M	0.32%	82
2022 Q1	$980M	Buy	5,999,674 +5,680,728	+1,781%	+$865M	0.17%	140
2021 Q4	$54.1M	Hold	318,946	–	–	0.01%	438
2021 Q3	$60.2M	Hold	318,946	–	–	0.01%	424
2021 Q2	$54.1M	Sell	318,946 -33,600	-10%	-$4.92M	0.01%	437
2021 Q1	$49.8M	Hold	352,546	–	–	0.01%	438
2020 Q4	$45.8M	Hold	352,546	–	–	0.01%	418
2020 Q3	$51.3M	Hold	352,546	–	–	0.01%	390
2020 Q2	$52.2M	Hold	352,546	–	–	0.01%	361
2020 Q1	$38.4M	Buy	352,546 +214,846	+156%	+$24.8M	0.01%	350
2019 Q4	$15.9M	Hold	137,700	–	–	﹤0.01%	443
2019 Q3	$11.1M	Hold	137,700	–	–	﹤0.01%	459
2019 Q2	$9.99M	Hold	137,700	–	–	﹤0.01%	487
2019 Q1	$12.9M	Hold	137,700	–	–	﹤0.01%	467
2018 Q4	$10M	Hold	137,700	–	–	﹤0.01%	471
2018 Q3	$12.1M	Hold	137,700	–	–	﹤0.01%	500
2018 Q2	$13.6M	Hold	137,700	–	–	﹤0.01%	485
2018 Q1	$16.4M	Hold	137,700	–	–	﹤0.01%	453
2017 Q4	$17.5M	Hold	137,700	–	–	﹤0.01%	443
2017 Q3	$16.2M	Hold	137,700	–	–	﹤0.01%	440
2017 Q2	$11M	Hold	137,700	–	–	﹤0.01%	467
2017 Q1	$7.06M	Hold	137,700	–	–	﹤0.01%	469
2016 Q4	$5.16M	Sell	137,700 -436,000	-76%	-$18.3M	﹤0.01%	470
2016 Q3	$38.9M	Hold	573,700	–	–	0.01%	358
2016 Q2	$31.8M	Sell	573,700 -1,364,903	-70%	-$86M	0.01%	368
2016 Q1	$122M	Hold	1,938,603	–	–	0.03%	259
2015 Q4	$183M	Sell	1,938,603 -5,000	-0.3%	-$464K	0.05%	237
2015 Q3	$156M	Sell	1,943,603 -113,000	-5%	-$12.6M	0.05%	252
2015 Q2	$247M	Sell	2,056,603 -82,097	-4%	-$9.81M	0.07%	225
2015 Q1	$223M	Buy	2,138,700 +1,173,388	+122%	+$119M	0.06%	234
2014 Q4	$93.6M	Buy	965,312 +116,612	+14%	+$10.8M	0.03%	304
2014 Q3	$66.3M	Hold	848,700	–	–	0.02%	342
2014 Q2	$53.6M	Sell	848,700 -16,000	-2%	-$951K	0.01%	350
2014 Q1	$58.1M	Sell	864,700 -190,000	-18%	-$14.7M	0.02%	339
2013 Q4	$67.8M	Sell	1,054,700 -158,300	-13%	-$9.44M	0.02%	330
2013 Q3	$77.6M	Sell	1,213,000 -487,000	-29%	-$24.3M	0.02%	312
2013 Q2	$52.7M	Buy	+1,700,000	New	+$45.2M	0.02%	333

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors's ALNY Position: Q1 2026 in Review

Capital World Investors reduced its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, selling an estimated $1.87B and leaving 10,802,348 shares worth $3.57B. The position accounts for 0.49% of the portfolio, ranked #53.

Capital World Investors first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.49B in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Capital World Investors held 10,802,348 shares of Alnylam Pharmaceuticals worth $3.57B as of Q1 2026.
Capital World Investors sold 5,499,424 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.87B.
Alnylam Pharmaceuticals made up 0.49% of Capital World Investors's portfolio in Q1 2026, its #53 holding.
Capital World Investors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Capital World Investors's Alnylam Pharmaceuticals position peaked at $7.49B in Q3 2025.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Capital World Investors's 13F filing for Q1 2026, filed 13 May 2026.